Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
As of close of business last night, Silk Road Medical Inc’s stock clocked out at $17.57, down -0.57% from its previous closing price of $17.67. In other words, the price has decreased by -$0.57 from its previous closing price. On the day, 0.52 million shares were traded. SILK stock price reached its highest trading level at $18.03 during the session, while it also had its lowest trading level at $17.46.
Ratios:
To gain a deeper understanding of SILK’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.97 and its Current Ratio is at 7.95. In the meantime, Its Debt-to-Equity ratio is 0.56 whereas as Long-Term Debt/Eq ratio is at 0.55.
On January 19, 2024, Stifel Upgraded its rating to Buy which previously was Hold and also upped its target price recommendation from $9 to $20.
On January 03, 2024, Lake Street started tracking the stock assigning a Buy rating and target price of $20.Lake Street initiated its Buy rating on January 03, 2024, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 05 ’24 when Ballinger Kevin J. bought 11,700 shares for $16.99 per share. The transaction valued at 198,783 led to the insider holds 17,807 shares of the business.
Buchanan Lucas W. sold 9,877 shares of SILK for $169,578 on Mar 05 ’24. The COO/CFO now owns 500,925 shares after completing the transaction at $17.17 per share. On Mar 05 ’24, another insider, Davis Andrew S., who serves as the Chief Commercial Officer of the company, sold 5,481 shares for $17.17 each. As a result, the insider received 94,103 and left with 287,773 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SILK now has a Market Capitalization of 690648576 and an Enterprise Value of 591457024. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.89 while its Price-to-Book (P/B) ratio in mrq is 4.55. Its current Enterprise Value per Revenue stands at 3.339 whereas that against EBITDA is -10.454.
Stock Price History:
Over the past 52 weeks, SILK has reached a high of $46.57, while it has fallen to a 52-week low of $6.08. The 50-Day Moving Average of the stock is 0.92%, while the 200-Day Moving Average is calculated to be 15.32%.
Shares Statistics:
It appears that SILK traded 751.23K shares on average per day over the past three months and 456550 shares per day over the past ten days. A total of 39.17M shares are outstanding, with a floating share count of 36.56M. Insiders hold about 6.67% of the company’s shares, while institutions hold 105.83% stake in the company. Shares short for SILK as of 1711584000 were 4088195 with a Short Ratio of 5.44, compared to 1709164800 on 4322476. Therefore, it implies a Short% of Shares Outstanding of 4088195 and a Short% of Float of 10.6300004.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 8.0 analysts currently analyzing and rating the stock of Silk Road Medical Inc (SILK).On average, analysts expect EPS of -$0.4 for the current quarter, with a high estimate of -$0.36 and a low estimate of -$0.42, while EPS last year was -$0.43. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.32 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.32 and -$1.5 for the fiscal current year, implying an average EPS of -$1.39. EPS for the following year is -$1.3, with 10.0 analysts recommending between -$1.17 and -$1.57.
Revenue Estimates
In the current quarter, 9 analysts expect revenue to total $44.68M. It ranges from a high estimate of $45M to a low estimate of $43.8M. As of the current estimate, Silk Road Medical Inc’s year-ago sales were $40.69MFor the next quarter, 9 analysts are estimating revenue of $49.07M. There is a high estimate of $50.1M for the next quarter, whereas the lowest estimate is $47.6M.
A total of 9 analysts have provided revenue estimates for SILK’s current fiscal year. The highest revenue estimate was $196.7M, while the lowest revenue estimate was $194M, resulting in an average revenue estimate of $195.92M. In the same quarter a year ago, actual revenue was $177.13MBased on 9 analysts’ estimates, the company’s revenue will be $217.79M in the next fiscal year. The high estimate is $225.41M and the low estimate is $213M.
